Leigh Zawel

Pathways Behavioral Services — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

31h-index11.6kcitations152works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell death mechanisms and regulation(32), Melanoma and MAPK Pathways(26), Neutrophil, Myeloperoxidase and Oxidative Mechanisms(18), Acute Myeloid Leukemia Research(17), Phagocytosis and Immune Regulation(17)

Publications152 total

Supplementary Methods from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Figures S1 - S7 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Data from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Information Figure S3 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S2 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S5 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information text S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Table S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Methods from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figure Legend from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
2023Open Access
Supplementary Information Figure S5 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Table S9 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Tables S1 - S8 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figures S1 - S7 from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Data from Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma
2023Open Access
Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Information Figure S4 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Data from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Figure Legends, Table Legends, Figure 1, Tables 1 - 4 from Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Stephen E. Fawell(11), Danny Reinberg(10), Dale Porter(7), Bert Vogelstein(6), Joanna Slisz(6), Kenneth W. Kinzler(5), David Witter(5), Christopher Straub(5), Theresa Zhang(5), Andrew L. Kung(5), Shibin Zhou(4), Brian J. Long(4), Minilik Angagaw(4), Mary Tran(4), Heather A. Hirsch(4), Gary Gilliland(4), Brant Firestone(4), Constantine S. Mitsiades(4), Peter R. Strack(4), Zofia Piotrowska(4)